Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do We Sin When Treating Patients with Higher-Risk Myelodysplastic Syndromes?

Transplantation and cellular therapy·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Myelodysplastic syndrome with concomitant <i>SF3B1</i> mutation and deletion of chromosome 5 long arm: outcomes and response to treatment.

Haematologica·2026
Same author

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial.

Blood neoplasia·2026
Same author

Not guilty by association: myelodysplasia-related mutations in AML.

Leukemia·2026

Related Experiment Video

Updated: Jul 19, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Immunomodulation in myelodysplastic syndromes.

Mikkael A Sekeres1, Alan List

  • 1Cleveland Clinic Lerner College of Medicine, Department of Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. sekerem@ccf.org

Best Practice & Research. Clinical Haematology
|September 26, 2006
PubMed
Summary

Myelodysplastic syndromes (MDS) involve bone marrow stem cell issues causing low blood counts. Targeting inflammatory cytokines shows promise for treating low-risk MDS and improving patient outcomes.

More Related Videos

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Jul 19, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) are bone marrow stem cell malignancies.
  • MDS is characterized by peripheral-blood cytopenias and maturation arrest.
  • Ineffective hematopoiesis in MDS is worsened by inflammatory cytokines.

Purpose of the Study:

  • To explore the role of inflammatory cytokines in MDS pathogenesis.
  • To review current research on abrogating cytokine effects in low-risk MDS.
  • To identify potential therapeutic strategies for MDS treatment.

Main Methods:

  • Literature review of clinical trials and research studies.
  • Analysis of pathogenetic overlap between MDS and acute myeloid leukemia.
  • Evaluation of therapeutic agents targeting cytokine pathways.

Main Results:

  • Premature apoptosis contributes to ineffective hematopoiesis in MDS.
  • Stromal cytokine production exacerbates MDS pathology.
  • Agents like thalidomide, lenalidomide, and infliximab show efficacy.

Conclusions:

  • Abrogating inflammatory cytokine effects is a key research area for MDS.
  • Targeted therapies demonstrate promising efficacy and tolerability.
  • These agents may form the basis for future combination treatments in MDS.